EMA Authorised: Ibandronic acid Accord (ibandronic acid) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Accord Healthcare S.L.U.'s ibandronic acid product under a marketing authorization. The approval covers indications related to calcium metabo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer with Bone Metastases
• Hypercalcemia of Malignancy
• Osteoporosis

Drugs mentioned

• Ibandronic acid Accord (ibandronic acid)

Snippet

Status: Authorised. Therapeutic area: Wounds and Injuries;Breast Diseases;Neoplastic Processes;Calcium Metabolism Disorders;Water-Electrolyte Imbalance. MAH: Accord Healthcare S.L.U.. Decision date: 25/09/2025